Using CD45RA Depleted Stem Cells to Prevent Infections After Transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of CD45RA depleted stem cells to enhance immune recovery and reduce the risk of infections following hematopoietic stem cell transplantation (HSCT) in patients with high-risk leukemia and other conditions. The study aims to determine the maximum tolerated dose of CD45RO memory T lymphocytes added back to the transplant process, which may help accelerate immune reconstitution. It includes both phase 1 and phase 2 components, focusing on patients receiving cells from mismatched or haploidentical related donors. The trial builds on previous research and expands eligibility to include a broader range of transplant indications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Disease for which allogeneic HSCT may be curative.
2. Remission status of hematologic malignancies and additional disease-specific eligibility determinations will be according to standards of practice within the CHOP Cellular Immunotherapy and Transplant Program (CTTS).
3. Patients must be 25 years of age and less
4. Evaluation for organ and infectious status as per our CTTS standard operating procedure.
5. Signed consent by parent/guardian or able to give consent if 18 years of age and older.
6. Participants of childbearing potential must have a negative pregnancy test as per institutional SOP.

Exclusion Criteria:

1. Patients who have performance score less than 60.
2. No suitable donor available for mobilized peripheral stem cells.
3. Patients with Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma.
4. Planned receipt of alemtuzumab during conditioning.
5. Patients with an available 10/10 HLA matched sibling donor.
6. Patients who do not meet institutional disease, organ or infectious criteria.

Donor selection and eligibility:

1. Unrelated donor meets National Marrow Donor Program criteria for donation.
2. Related donor (at least haploidentical) willing and able to donate mobilized peripheral stem cells.
3. HLA testing/matching

   * HLA testing to be done by molecular methods for A, B, C, DRB1, DQB1
   * Related donor: Must be ≥ 5/10 match
   * Unrelated donor: 10/10 or 9/10 match
   * KIR typing for haploidentical donor for hematologic malignancies
   * Donor specific HLA antibodies (DSA) should be assessed for all subjects receiving an HLA mismatched graft (≤ 9/10).
4. Donor must be willing to undergo granulocyte colony stimulating factor (GCSF) mobilization and peripheral blood stem cell collection
5. Donors must be willing to sign consent to participate in this study.

Where it's running

• Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Timothy Olson, MD, PhD — Children's Hospital of Philadelphia
• Study coordinator: Megan Atkinson
• Email: cttsbmtintake@chop.edu
• Phone: 215-590-2820

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cord blood transplant for children and young adults with blood cancers and disorders

  This study is testing a new treatment using chemotherapy followed by a cord blood transplant to see if it can help children and young adults with serious blood cancers and disorders who don't have a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT04644016

• Understanding congenital bone marrow failure and related disorders through a national network

  This project tests whether people with rare inherited bone marrow failure syndromes or related conditions really have the underlying genetic causes, by collecting data and samples across multiple centers.

  Recruiting at 4 sites Istituto Giannina Gaslini · Avellino and 3 other locations · NCT07877727

• Revumenib with Mezigdomide for relapsed or refractory acute leukemia

  This trial will test whether combining revumenib and mezigdomide is safe for people aged 12 and older with relapsed or refractory acute leukemia that has KMT2A, NUP98, or NPM1 genetic changes.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT07356154

• CG009301 for adults with relapsed or treatment‑resistant blood cancers

  This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 Cullgen (Shanghai),Inc · Nanchang and 2 other locations · NCT07347171

• HOPE Biobank: connecting blood disease patients through stem cell transplant and gene therapy samples

  This study will collect blood and other biospecimens along with clinical data from people undergoing stem cell transplant or gene therapy for non-cancer blood diseases to build a large biobank for future research.

  Recruiting at 14 sites Medical College of Wisconsin · Duarte, California and 13 other locations · NCT07227155

• Platform for Rare Blood Disorders in Europe

  This study is trying to gather and share information about rare blood disorders across Europe to help researchers understand these conditions better and improve treatment options for patients.

  Recruiting Hospital Universitari Vall d'Hebron Research Institute · Barcelona, Catalonia · NCT06250595

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.